What does APOTHEEK LOKSBERGEN do?

APOTHEEK LOKSBERGEN is a pharmacy in Halen. Private Limited, started on 9 July 2001, 1 establishment.

What is the address of APOTHEEK LOKSBERGEN?

The registered office of APOTHEEK LOKSBERGEN is located at Loksbergenstraat 61, 3545 Halen.

Is APOTHEEK LOKSBERGEN still active?

Yes. According to the CBE (31 October 2026) APOTHEEK LOKSBERGEN is active, legal situation “Normale toestand”, started on 9 July 2001.

Is APOTHEEK LOKSBERGEN registered on Peppol?

Yes, APOTHEEK LOKSBERGEN is registered on the Peppol network with ID 0208:0475244669.

What is the enterprise number of APOTHEEK LOKSBERGEN?

The enterprise number of APOTHEEK LOKSBERGEN is BE0475244669.

When was APOTHEEK LOKSBERGEN founded?

APOTHEEK LOKSBERGEN was founded on 9 July 2001.

Who are the directors of APOTHEEK LOKSBERGEN?

According to the 2025 annual accounts, the directors of APOTHEEK LOKSBERGEN are: G&Pharma BV.

Is APOTHEEK LOKSBERGEN a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 9 July 2001; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did APOTHEEK LOKSBERGEN make in 2025?

APOTHEEK LOKSBERGEN posted a profit after taxes of € 135,102 in financial year 2025.

What is the revenue of APOTHEEK LOKSBERGEN?

As a small company, APOTHEEK LOKSBERGEN is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 283,518.

APOTHEEK LOKSBERGEN (Private Limited) - Halen

Dossier APOTHEEK LOKSBERGEN, printed on 31 October 2026 from databakkes.be/en/0475244669/apotheek-loksbergen. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

APOTHEEK LOKSBERGEN from Halen, company number BE0475244669, closed financial year 2025 with a result of € 135,102 after tax. For that financial year APOTHEEK LOKSBERGEN recorded a gross margin of € 283,518 and equity of € 258,746. Compared with financial year 2024, the result moved from € 99,172 to € 135,102. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 8, 2026.

What it is worth Growing

€ 258,746

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 135,102

▲ 36% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 152,472

▲ 24% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 135,000 paid out

100 % of the profit went to the shareholders, mostly to G & PHarma (100 % of the shares). That is where the money ends up.

People and assets in 2025

Vehicles and equipment

€ 39,051

▼ 22% vs 2024

Of which on lease € 31,394.

Debts at end 2025

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 588,319

▼ 16% vs 2024

€ 92,558 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 103,813

▼ 5% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 2,415

▼ 52% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 239,557 Gross margin 2022: € 239,557 First fiscal year in the series	€ 229,510 Gross margin 2023: € 229,510 ▼ 4% vs 2022 (€ 239,557) Unfavourable step	€ 254,094 Gross margin 2024: € 254,094 ▲ 11% vs 2023 (€ 229,510) Favourable step	€ 283,518 Gross margin 2025: € 283,518 ▲ 12% vs 2024 (€ 254,094) Favourable step	▲ 12%
Profit after taxes	€ 108,943 Profit after taxes 2022: € 108,943 First fiscal year in the series	€ 67,697 Profit after taxes 2023: € 67,697 ▼ 38% vs 2022 (€ 108,943) Unfavourable step	€ 99,172 Profit after taxes 2024: € 99,172 ▲ 46% vs 2023 (€ 67,697) Favourable step	€ 135,102 Profit after taxes 2025: € 135,102 ▲ 36% vs 2024 (€ 99,172) Favourable step	▲ 36%
Equity	€ 257,275 Equity 2022: € 257,275 First fiscal year in the series	€ 257,973 Equity 2023: € 257,973 Unchanged (€ 257,275) Favourable step	€ 258,645 Equity 2024: € 258,645 Unchanged (€ 257,973) Favourable step	€ 258,746 Equity 2025: € 258,746 Unchanged (€ 258,645) Favourable step
Total debts	€ 1,130,742 Total debts 2022: € 1,130,742 First fiscal year in the series	€ 991,239 Total debts 2023: € 991,239 ▼ 12% vs 2022 (€ 1,130,742) Favourable step	€ 922,176 Total debts 2024: € 922,176 ▼ 7% vs 2023 (€ 991,239) Favourable step	€ 888,408 Total debts 2025: € 888,408 ▼ 4% vs 2024 (€ 922,176) Favourable step	▼ 4%
Cash	€ 157,621 Cash 2022: € 157,621 First fiscal year in the series	€ 89,059 Cash 2023: € 89,059 ▼ 43% vs 2022 (€ 157,621) Unfavourable step	€ 122,732 Cash 2024: € 122,732 ▲ 38% vs 2023 (€ 89,059) Favourable step	€ 152,472 Cash 2025: € 152,472 ▲ 24% vs 2024 (€ 122,732) Favourable step	▲ 24%
Land & buildings	€ 833,350 Land & buildings 2022: € 833,350 First fiscal year in the series	€ 740,735 Land & buildings 2023: € 740,735 ▼ 11% vs 2022 (€ 833,350) Unchanged	€ 631,448 Land & buildings 2024: € 631,448 ▼ 15% vs 2023 (€ 740,735) Unchanged	€ 551,530 Land & buildings 2025: € 551,530 ▼ 13% vs 2024 (€ 631,448) Unchanged	▼ 13%
Retained profit	€ 244,875 Retained profit 2022: € 244,875 First fiscal year in the series	€ 245,573 Retained profit 2023: € 245,573 Unchanged (€ 244,875) Favourable step	€ 246,245 Retained profit 2024: € 246,245 Unchanged (€ 245,573) Favourable step	€ 246,346 Retained profit 2025: € 246,346 Unchanged (€ 246,245) Favourable step
Dividend	€ 55,000 Dividend 2022: € 55,000 First fiscal year in the series	€ 67,000 Dividend 2023: € 67,000 ▲ 22% vs 2022 (€ 55,000) Unchanged	€ 98,500 Dividend 2024: € 98,500 ▲ 47% vs 2023 (€ 67,000) Unchanged	€ 135,000 Dividend 2025: € 135,000 ▲ 37% vs 2024 (€ 98,500) Unchanged	▲ 37%
Bank debt	€ 864,803 Bank debt 2022: € 864,803 First fiscal year in the series	€ 803,050 Bank debt 2023: € 803,050 ▼ 7% vs 2022 (€ 864,803) Favourable step	€ 701,259 Bank debt 2024: € 701,259 ▼ 13% vs 2023 (€ 803,050) Favourable step	€ 588,319 Bank debt 2025: € 588,319 ▼ 16% vs 2024 (€ 701,259) Favourable step	▼ 16%
Balance sheet total	€ 1,388,018 Balance sheet total 2022: € 1,388,018 First fiscal year in the series	€ 1,249,212 Balance sheet total 2023: € 1,249,212 ▼ 10% vs 2022 (€ 1,388,018) Unchanged	€ 1,180,820 Balance sheet total 2024: € 1,180,820 ▼ 5% vs 2023 (€ 1,249,212) Unchanged	€ 1,147,154 Balance sheet total 2025: € 1,147,154 ▼ 3% vs 2024 (€ 1,180,820) Unchanged	▼ 3%

Key figures of APOTHEEK LOKSBERGEN, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to APOTHEEK LOKSBERGEN?

What happened at APOTHEEK LOKSBERGEN in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 8, 2026 New annual accounts for financial year 2025: profit of € 135,102 (▲ 36% vs 2024). Source: NBB ↗
2023 G&Pharma BV became a director. NBB
Sep 17, 2001 New establishment in Halen. KBO
Jul 9, 2001 Start of the company according to the CBE. KBO

In short

From € 108,943 profit in 2022 to € 135,102 profit in 2025.

Paid € 12,096 in corporate taxes since 2022.

Best year ever: 2025, with € 135,102 profit.

Paid out € 355,500 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

G & PHarma 100%

The stake of G & PHarma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

APOTHEEK LOKSBERGEN

Behind APOTHEEK LOKSBERGEN is G&Pharma BV. The shares are held by G & PHarma (100%).

Directors

According to the 2025 annual accounts

G&Pharma BV

Director · represented by Geertrui Put

since 2023

Shareholders

G & PHarma

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Loksbergenstraat 61

3545 Halen

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

G & PHarma same network

€ 275,713 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0475.244.669

VAT number

BE 0475.244.669

Registered office

Loksbergenstraat 61, 3545 Halen

Names & denominations

APOTHEEK LOKSBERGEN

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

9 July 2001

Peppol

Active · Active since 30 Aug 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

Overige niet-gespecialiseerde detailhandel

Detailhandel in cosmetica en toiletartikelen

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen

Detailhandel via postorderbedrijven of via internet

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗

APOTHEEK LOKSBERGEN

Financials

What happened to APOTHEEK LOKSBERGEN?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions